Ideally biomarkers provide the clinician with assistance in one or more of: (i) diagnosis, (ii) prognosis, (iii) choice and titration of therapy, 
; Figure 2 ). In people 50 years of age or less, an NT-proBNP level of 450 pg/ml or more in the presence of acute breathlessness is almost a perfect test for ADHF (area under the curve [AUC] 0.99). Of course, most of our HF patients are older and the AUC falls to 0.93 at 50 to 75 years (when the optimal test level is 900 pg/ml) and to 0.86 for those over 75 years (1,800 pg/ml).
These age-adjusted values are well-validated for NT-proBNP, but have not been formally addressed for BNP. 5 Second, whether or not left ventricular ejection fraction (LVEF) is reduced (HFrEF) or preserved (HFpEF) in HF influences plasma B-type natriuretic peptides, with levels in HFpEF being approximately half those seen in HFrEF (see Table 1 ) in both AHF and CHF. [7] [8] [9] This 12-14 The discriminative power of BNP/NT-proBNP for ADHF in newly dyspnoeic patients is clearly reduced with AUCs falling from about 0.9 for those in sinus rhythm to ~0.7 in AF (see Figure 3) . 15 Sensitivity is preserved (because overall NP levels are raised by AF), but specificity and accuracy are markedly reduced and cannot be improved by merely altering the cut-point chosen although some suggest a higher decision level of 200 pg/ml for BNP in AF. In fact between 65 and 85 % of breathless patients presenting acutely with complicating AF with B peptide levels above 100 pg/ml and 300 pg/ml for BNP and NT-proBNP, respectively, will indeed have HF and it is rational to regard such patients as having ADHF until proved otherwise. [12] [13] [14] [15] Fourth, body mass index (BMI) is inversely related to plasma NP concentrations in both health and HF. The underlying mechanisms are not understood. [16] [17] [18] Unlike renal impairment or AF, obesity leaves the overall discrimination of BNP for AHF largely preserved with AUCs only moving from 0.9 to 0.88 between BMI <25 and >35 kg/m 2 . The effect is sufficiently strong to reduce the sensitivity of BNP at 100 pg/ml and analysis from the trial led to a recommendation to reduce the cut-point to 50 pg/ml where obesity (i.e. BMI >30 kg/m 2 ) is present (see Figure 4) . 18 Test performance of NT-proBNP appears less affected by obesity. 17 Fifth, plasma creatinine and estimated glomerular filtration rate (eGFR) are inversely related to plasma NP levels. 4, 5, 19 This is a sufficiently strong effect to lead to the recommendation that the cut-point for BNP should be increased to 200 pg/ml when eGFR falls below 60 ml/min/1.73m 2 . 20 No specific corresponding change in cutpoint is generally applied to NT-proBNP values and the performance of NT-proBNP is less affected (see Table 2 ). 20 For both markers, specificity and accuracy are somewhat reduced regardless of any alternative choice of decision thresholds. in acute and CHF and they offer more fine-grained risk stratification when combined with BNP/NT-proBNP. 2,21-23 MR-proADM in particular is superior to BNP/NT-proBNP for prediction of mortality in the first 30 days after onset of ADHF. 6, 24 At the time of writing there is no new marker that offers diagnostic performance superior to BNP/NT-proBNP.
Kidney
ADHF is associated with a high incidence (~25 %) of AKI, often superimposed on pre-existing chronic renal impairment. In unselected series half of patients with CHF have an estimated eGFR below 60 ml/min/1.73m 2 .
25,26 AKI usually manifests in the first few days of admission and is most commonly regarded as type 1 cardiorenal syndrome defined as acute impairment of renal function secondary to acute cardiac insufficiency. Both background renal dysfunction and any acute decrement portend a worse prognosis in ADHF. [25] [26] [27] [28] Since 2000, reports from several large series consistently indicate that AKI, defined as an increment in plasma creatinine of over 0.3 mg/dl (i.e. 26.4 µmol/l), is associated with a near doubling of mortality at 1 year and increments in creatinine as little as 0.1 mg/ dl (9 µmol/l) are associated with worse prognosis. 28 Although efforts to date to target AKI in ADHF with specific pharmacotherapies have been disappointing, 29 awareness of developing kidney injury in ADHF can trigger supportive measures (avoidance of nephrotoxic drugs and contrast media, avoidance of hypotension, careful titration of any measures influencing volume and pressure homeostasis) and resulting in improved outcomes. 30 Unfortunately, dependence on serial measurement of plasma creatinine to monitor renal status delays awareness of AKI by 24-72 hours. A major cause of failed intervention trials in AKI is delayed intervention resulting from the delay inherent in the use of creatinine as the diagnostic surrogate of reduced GFR, and the misconception that loss of filtration function is an early rather than a late sign of renal injury. 31 Further, many patients with a near-normal serum creatinine level on admission with ADHF have evolving AKI, not apparent due to absence of information on pre-admission baseline values. In addition, whether AKI in HF from hypoperfusion differs from injury resulting from renal venous congestion is unclear. 32 Hence there is an important unmet need for early markers of AKI in AHF in order to allow timely introduction of supportive measures and to target later experimental therapies for AKI in ADHF. 
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NGAL has claimed particular attention in recent years, but published reports consistently indicate the AUC for detection of AKI in ADHF using urine or serum NGAL is ~0.7. [36] [37] [38] [39] In order to offer meaningful clinical advantage, markers generally require AUCs in the order of 0.75 or more. In this regard exciting recent data from a trial in patients with heterogenous forms of serious acute disease indicate that the cell cycle markers insulin growth factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases type 2 (TIMP-2) perform at this level with AUC for detection of AKI of ~0.8 (see Figure 5) . 40 These new markers have not been tested specifically in an ADHF population. 
Conclusions

